Precigen, Inc. (PGEN)
| Market Cap | 2.69B +140.8% |
| Revenue (ttm) | 85.72M +1,875.0% |
| Net Income | -336.71M |
| EPS | -0.98 |
| Shares Out | 358.04M |
| PE Ratio | n/a |
| Forward PE | 13.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,982,918 |
| Open | 7.95 |
| Previous Close | 7.89 |
| Day's Range | 7.19 - 8.01 |
| 52-Week Range | 2.99 - 8.04 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 14.48 (+92.68%) |
| Est. Earnings | Nov 12, 2026 |
About PGEN
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro... [Read more]
Financial Performance
In 2025, Precigen's revenue was $9.68 million, an increase of 146.73% compared to the previous year's $3.93 million. Losses were -$429.64 million, 240.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price target is $14.48, which is an increase of 92.68% from the latest price.
News
Precigen says FDA grants platform technology designation to AdenoVerse platform
Precigen (PGEN) announced that the United States FDA granted platform technology designation to the AdenoVerse immunotherapeutic platform, which is used in the company’s first commercial product, Papz...
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: ...
Precigen Q2 marked commercial inflection
For Precigen (PGEN), the second quarter marked a commercial inflection. PAPZIMEOS generated $53.1 M in net product revenue-more than double the prior quarter-and helped the company achieve quarterly p...
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the...
Precigen price target raised to $18 from $14 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $18 from $14 and keeps a Buy rating on the shares post the Q2 beat. The company’s Papzimeos sales…
Precigen Earnings Call Transcript: Q2 2026
Q2 2026 saw PAPZIMEOS revenue surge over 145% sequentially to $53.1 million, driving profitability and broad adoption as the new RRP standard of care. Gross margin reached 95%, with strong payer coverage and continued growth expected as the launch matures.
Precigen Earnings release: Q2 2026
Precigen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Precigen Quarterly report: Q2 2026
Precigen has published its Q2 2026 quarterly earnings report on August 4, 2026.
Precigen reports Q2 EPS 5c vs., (9c) last year
Reports Q2 revenue $55.0M, consensus $27.83M. “We delivered a historic Q2, with the rapid adoption of PAPZIMEOS demonstrating the strength of our groundbreaking science and innovative commercial strat...
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoption PAPZIMEOS revenue propelled ...
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve ...
Precigen Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and an incentive plan amendment, with all proposals passing by large margins. No shareholder questions or comments were received during the proceedings.
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rar...
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with R...
Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Innovative gene therapy platforms have enabled rapid approval and launch of a first-in-class treatment for RRP, achieving strong clinical outcomes and broad market uptake. Expansion into pediatric, European, and oncology markets is underway, with additional data readouts expected in Q4.
Precigen presents long-term follow-up data from study of Papzimeos
Precigen (PGEN) announced updated long-term follow-up data from the study of Papzimeos for the treatment of adults with recurrent respiratory papillomatosis, RRP. Updated durability of response data w...
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4 ...
Precigen price target raised to $14 from $11 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $14 from $11 and keeps a Buy rating on the shares. The company announced that the FDA granted Papzimeos…
Precigen receives orphan drug exclusivity for papzimeos in the U.S.
Precigen (PGEN) announced that the FDA has granted orphan drug exclusivity for papzimeos – zopapogene imadenovec-drba – for the treatment of adults with recurrent respiratory papillomatosis, or RRP. P...
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14,...
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve t...
Precigen price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $11 from $10 and keeps a Buy rating on the shares post the Q1 report. The firm says Papzimeos…
Precigen price target raised to $11 from $9 at Citizens
Citizens raised the firm’s price target on Precigen (PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm is impressed by the strength of the…
Precigen reports Q1 EPS (2c) vs. (18c) last year
Reports Q1 revenue $23.25M, consensus $20.8M. “We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the…
Precigen Earnings Call Transcript: Q1 2026
PAPZIMEOS achieved $21.6M in Q1 2026 revenue, marking rapid adoption as the new RRP standard of care, with broad payer coverage and strong physician enthusiasm. Cash position is solid, with operations funded through 2026 and continued expansion expected.